| Literature DB >> 31969690 |
Benzhi Cai1,2, Wenya Ma3, Xiuxiu Wang3, Natalia Sukhareva3, Bingjie Hua3, Lai Zhang3, Juan Xu4, Xingda Li3, Shuainan Li3, Shenzhen Liu3, Meixi Yu3, Yan Xu3, Ruijie Song3, Binbin Xu3, Fan Yang3, Zhenbo Han3, Fengzhi Ding3, Qi Huang3, Ying Yu3, Yue Zhao3, Jin Wang3, Djibril Bamba3, Naufal Zagidullin5, Faqian Li6, Ye Tian7, Zhenwei Pan8, Baofeng Yang9.
Abstract
Neonatal mammalian heart maintains a transient regeneration capacity after birth, whereas this regeneration ability gradually loses in the postnatal heart. Thus, the reactivation of cardiomyocyte proliferation is emerging as a key strategy for inducing heart regeneration in adults. We have reported that a highly conserved long noncoding RNA (lncRNA) LncDACH1 was overexpressed in the failing hearts. Here, we found that LncDACH1 was gradually upregulated in the postnatal hearts. Cardiac-specific overexpression of LncDACH1 (TG) in mice suppressed neonatal heart regeneration and worsened cardiac function after apical resection. Conversely, in vivo cardiac conditional knockout of LncDACH1 (CKO) and adenovirus-mediated silencing of endogenous LncDACH1 reactivated cardiomyocyte-proliferative potential and promoted heart regeneration after myocardial infarction (MI) in juvenile and adult mice. Mechanistically, LncDACH1 was found to directly bind to protein phosphatase 1 catalytic subunit alpha (PP1A), and in turn, limit its dephosphorylation activity. Consistently, PP1A siRNA or pharmacological blockers of PP1A abrogated cardiomyocyte mitosis induced by LncDACH1 silencing. Furthermore, LncDACH1 enhanced yes-associated protein 1 (YAP1) phosphorylation and reduced its nuclear translocation by binding PP1A. Verteporfin, a YAP1 inhibitor decreased LncDACH1 silencing-induced cardiomyocyte proliferation. In addition, targeting a conserved fragment of LncDACH1 caused cell cycle re-entry of human iPSC-derived cardiomyocytes. Collectively, LncDACH1 governs heart regeneration in postnatal and ischemic hearts via regulating PP1A/YAP1 signal, which confers a novel therapeutic strategy for ischemic heart diseases.Entities:
Year: 2020 PMID: 31969690 PMCID: PMC7308407 DOI: 10.1038/s41418-020-0492-5
Source DB: PubMed Journal: Cell Death Differ ISSN: 1350-9047 Impact factor: 15.828